DK1146896T3 - Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger - Google Patents

Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Info

Publication number: DK1146896T3
Authority: DK; Denmark
Prior art keywords: human insulin; modified; acylated; formulations; formulations containing
Prior art date: 1999-01-26

Application number

DK00904496T

Other languages

English (en)

Inventor

Kingman Ng

Shun Li

Eric Alan Watts

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-26

Filing date

2000-01-26

Publication date

2002-09-02

2000-01-26 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2002-09-02 Application granted granted Critical

2002-09-02 Publication of DK1146896T3 publication Critical patent/DK1146896T3/da

Links

238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 4
239000007864 aqueous solution Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
101500025353 Homo sapiens Insulin A chain Proteins 0.000 abstract 1
101500025354 Homo sapiens Insulin B chain Proteins 0.000 abstract 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
125000005313 fatty acid group Chemical group 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DK00904496T 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger DK1146896T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11729199P	1999-01-26	1999-01-26
PCT/US2000/001627 WO2000043034A2 (en)	1999-01-26	2000-01-26	Monodisperse hexameric acylated insulin analog formulations

Publications (1)

Publication Number	Publication Date
DK1146896T3 true DK1146896T3 (da)	2002-09-02

Family

ID=22372048

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00904496T DK1146896T3 (da)	1999-01-26	2000-01-26	Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Country Status (9)

Country	Link
EP (1)	EP1146896B1 (da)
JP (1)	JP2002535287A (da)
AT (1)	ATE220917T1 (da)
AU (1)	AU2624400A (da)
DE (1)	DE60000288T2 (da)
DK (1)	DK1146896T3 (da)
ES (1)	ES2180511T3 (da)
PT (1)	PT1146896E (da)
WO (1)	WO2000043034A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169889B1 (en)	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US6835802B2 (en)	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
WO2003094956A1 (en) *	2002-05-07	2003-11-20	Novo Nordisk A/S	Soluble formulations comprising monomeric insulin and acylated insulin
AU2003218635A1 (en) *	2002-05-07	2003-11-11	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
US7648962B2 (en)	2002-11-26	2010-01-19	Biocon Limited	Natriuretic compounds, conjugates, and uses thereof
SG159387A1 (en)	2002-11-26	2010-03-30	Biocon Ltd In	Modified natriuretic compounds, conjugates, and uses thereof
CN101027318B (zh) *	2004-07-19	2016-05-25	比奥孔有限公司	胰岛素-低聚物共轭物，制剂及其用途
EP1969004B1 (en)	2005-12-28	2011-08-10	Novo Nordisk A/S	Compositions comprising an acylated insulin and zinc and method of making the said compositions
CN101573133B (zh)	2006-07-31	2014-08-27	诺沃-诺迪斯克有限公司	Peg化延长的胰岛素
CN101541830A (zh)	2006-09-22	2009-09-23	诺沃-诺迪斯克有限公司	蛋白酶抗性的胰岛素类似物
WO2008132224A2 (en)	2007-04-30	2008-11-06	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
CN101970477B (zh)	2008-03-14	2014-12-31	诺沃-诺迪斯克有限公司	蛋白酶稳定的胰岛素类似物
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
CN102202683A (zh)	2008-10-30	2011-09-28	诺沃-诺迪斯克有限公司	用少于每日一次的注射频率注射胰岛素来治疗糖尿病
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2836508B1 (en)	2012-04-11	2016-06-29	Novo Nordisk A/S	Insulin formulations
EP2919804B1 (fr)	2012-11-13	2018-01-31	Adocia	Formulation à action rapide d'insuline comprenant un composé anionique substitué
EP2991672A1 (en)	2013-04-30	2016-03-09	Novo Nordisk A/S	Novel administration regime
CA2926701A1 (en)	2013-10-07	2015-04-16	Novo Nordisk A/S	Novel derivative of an insulin analogue
AR102869A1 (es)	2014-12-16	2017-03-29	Lilly Co Eli	Composiciones de insulina de rápida acción
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
ES2886837T3 (es)	2016-12-16	2021-12-21	Novo Nordisk As	Composiciones farmacéuticas que contienen insulina
CA3065308C (en)	2017-06-01	2022-05-17	Eli Lilly And Company	Rapid-acting insulin compositions
CA3071686A1 (en)	2017-08-17	2019-02-21	Novo Nordisk A/S	Novel acylated insulin analogues and uses thereof
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
EP4013778A4 (en) *	2019-08-16	2023-09-13	Lamark Biotech PVT Limited	FORMULATION OF INSULIN BASED ON CRYSTAL VACCINATION OF HYDROGELS AND METHOD THEREOF
CN121752601A (zh) *	2023-09-20	2026-03-27	上海迈晋生物医药科技有限公司	一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
US20260216297A1 (en) *	2024-10-29	2026-07-30	Portal Diabetes Inc.	Stabilized formulations of insulin and insulin analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228094B1 (en) *	1996-06-20	2012-10-29	Novo Nordisk As	Insulin preparations containing nacl
ATE294189T1 (de) *	1997-02-07	2005-05-15	Novo Nordisk As	Kristallisation von proteinen
DE69924232D1 (de) *	1998-01-09	2005-04-21	Novo Nordisk As	Stabilisierte insulin-zubereitungen

2000
- 2000-01-26 JP JP2000594487A patent/JP2002535287A/ja not_active Withdrawn
- 2000-01-26 WO PCT/US2000/001627 patent/WO2000043034A2/en not_active Ceased
- 2000-01-26 DK DK00904496T patent/DK1146896T3/da active
- 2000-01-26 DE DE60000288T patent/DE60000288T2/de not_active Expired - Fee Related
- 2000-01-26 ES ES00904496T patent/ES2180511T3/es not_active Expired - Lifetime
- 2000-01-26 PT PT00904496T patent/PT1146896E/pt unknown
- 2000-01-26 AT AT00904496T patent/ATE220917T1/de not_active IP Right Cessation
- 2000-01-26 EP EP00904496A patent/EP1146896B1/en not_active Expired - Lifetime
- 2000-01-26 AU AU26244/00A patent/AU2624400A/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60000288T2 (de)	2003-01-16
JP2002535287A (ja)	2002-10-22
WO2000043034A3 (en)	2000-12-28
WO2000043034A2 (en)	2000-07-27
AU2624400A (en)	2000-08-07
EP1146896A2 (en)	2001-10-24
EP1146896B1 (en)	2002-07-24
ES2180511T3 (es)	2003-02-16
PT1146896E (pt)	2002-10-31
ATE220917T1 (de)	2002-08-15
DE60000288D1 (de)	2002-08-29

Publication	Publication Date	Title
ES2180511T3 (es)	2003-02-16	Formulaciones monodispersas de analogos de insulina acilados hexamericos.
WO2002043750A3 (en)	2002-10-31	Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
AU582920B2 (en)	1989-04-13	Continuous release pharmaceutical compositions
HUP0100243A2 (hu)	2001-08-28	Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
AU563642B2 (en)	1987-07-16	Oral antidiabetic composition
HU906177D0 (en)	1991-08-28	Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
CY1117668T1 (el)	2017-05-17	Φαρμακευτικες συστασεις περιλαμβανουσες ινσουλινη συμπλοκοποιημενη με μια δικετοπιπεραζινη
DE58901401D1 (de)	1992-06-17	Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
EP1234586A3 (en)	2003-04-09	Hepatoselective pharmaceutical actives
WO2007130113A3 (en)	2008-10-30	Parathyroid hormone analogues and methods of use
EP2308963A3 (en)	2011-09-21	System for processing lipoaspirate cells
PE19496A1 (es)	1996-06-01	Formulacion de analogo de insulina humana
TW200631592A (en)	2006-09-16	Soluble, stable insulin-containing formulations
BR9709845B1 (pt)	2008-11-18	preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
NO20005625L (no)	2001-01-05	Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
WO1996024370B1 (en)	1996-09-19	Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
IL207923A0 (en)	2011-07-31	Metal-binding compounds and uses therefor
BR9811755A (pt)	2000-08-29	Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
KR950700326A (ko)	1995-01-16	파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same)
CA2522146A1 (en)	2005-10-13	Uptake of macromolecules
DE60111637D1 (de)	2005-07-28	Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
AU7655098A (en)	1998-12-08	Somatostatin and somatostatin agonists for decreasing body weight
PT97878A (pt)	1992-12-31	Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais
MX9704388A (es)	1998-07-31	Incremento de la concentracion de creatina y glicogeno en musculos.
TH12479B (th)	2002-04-17	สูตรผสมของสารคล้ายอินซูลิน